The current landscape of asthma: A new geometry

Annals of Allergy, Asthma and Immunology

Volumn 89, Issue 4, 2002, Pages 337-339

  Wolf, Bruce L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL;

ASTHMA; BRONCHUS HYPERREACTIVITY; DISEASE EXACERBATION; DRUG POTENTIATION; EDITORIAL; INFLAMMATION; LUNG FUNCTION; POLYPHARMACY; PRIORITY JOURNAL; SMOOTH MUSCLE; SYMPTOMATOLOGY;

EID: 0036825261     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62029-7     Document Type: Editorial

References (10)

1. 2-adrenergic receptor agonists in primary lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999;274:1005-1010.
2. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000;320:1368-1373.
3. Kavuru M, Melamud J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000;105: 1108-1116.
4. Matz J, Emmett A, Rickard K, Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: An analysis of asthma exacerbations. J Allergy Clin Immunol 2001; 107:783-789.
5. Reed CE. The natural history of asthma in adults: the problem of irreversibility. J Allergy Clin Immunol 1999:103:539-547.
6. Olivieri D, Chetta A, Donno MD, et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo controlled study. Am J Respir Crit Care Med 1997;1555: 1864-1871.
7. Sue-Chu M, Wallin A, Wilson S, et al. Bronchial biopsy study in asthmatics treated with low and high dose fluticasone propionate (FP) compared to low dose FP combined with salmeterol. Eur Respir J 1999;14(Suppl):124S.
8. Li X, Ward C, Thien F, et al. An anti-inflammatory effect of salmeterol, a long-acting β2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 1999;160:1493-1499.
9. Leckie MJ, ten Brincke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness and the late asthmatic response. Lancet 2000;356:2144-2148.
10. Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999; 159:1.043-1051.